Accessibility Menu
Eikon Therapeutics logo

Eikon Therapeutics(NASDAQ) EIKN

Market Cap$631.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-22%
5 YearN/A
1 YearN/A
1 Month+19%
$13.98
+20.00%
+2.33Today
Eikon Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 11.652026-08-18
Eikon Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.88%USD 10.232026-08-11
1 month+19.24%USD 9.772026-07-17
3 month+9.29%USD 10.662026-05-20
Since inception-22.33%USD 15.002026-02-05

Eikon Therapeutics Financials at a Glance

Market Cap

$631.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$356.23

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.92 (High)

Price

$13.98

Volume

312,826.822

Open

$12.77

Previous Close

$11.65

Daily Range

$12.59 - $13.70

52-Week Range

$7.90 - $18.00

Estimated Earnings Date

Nov 12, 2026

EIKN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eikon Therapeutics

Eikon Therapeutics, Inc. makes medicines for serious diseases. It uses tools to watch proteins inside living cells. These treatments help people fighting various types of cancer.

Fighting Cancer at the Microscopic Level

  • EIK1001: Immune system booster targeting cancer; currently undergoing Phase 2 and Phase 3 clinical trials.
  • EIK1003 and EIK1004: Precision drugs for ovarian and breast cancers; designed to target the poly ADP-ribose polymerase 1 (PARP1) protein that repairs DNA.
  • EIK1005: Internal candidate for microsatellite instability-high (MSI-high) tumors; targets the Werner (WRN) helicase salvage pathway.
  • EIK1006: Experimental therapy for prostate cancer; expected to file an investigational new drug application (IND) by late 2026.

Building a Clinical Pipeline

  • In-licensed EIK1003 and EIK1004 from Impact Therapeutics in May 2023.
  • Partnered with MSD in Aug. 2024 and Dec. 2025 to test combinations for melanoma and non-small cell lung cancer (NSCLC).
  • Licensed candidates from Seven and Eight in March 2023 to develop toll-like receptor (TLR) agonists.
  • Completed an initial public offering in Feb. 2026, raising $348.1 million.

How Does Eikon Stand Out?

The company uses a proprietary single molecule tracking system to watch protein interactions in real time. This engineering-led approach aims to speed up drug discovery for complex diseases.

Tracking the Financial Health

  • Net loss was $171.4 million in the six-month period ended June 30, 2026, down 1% year over year.
  • Cash and marketable securities were $531.2 million as of June 30, 2026.
  • Research and development expenses were $145.5 million in the six-month period ended June 30, 2026, up 16% year over year.
  • Accumulated deficit reached $1.1 billion as of June 30, 2026.

Evolution Into a Clinical Organization

Eikon has transitioned from a discovery startup to a clinical-stage organization with multiple human trials. This evolution supports its goal of creating more precise treatments through advanced engineering.

AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Roger M. Perlmutter, MD, PhD

Website

www.eikontx.com

Headquarters

Millbrae, CA 94030, US

EIKN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

150.71%

Return on Capital

N/A

Return on Assets

-32.20%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$631.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

54.16M

Volume

312.83K

Avg. Volume

378.88K

Financials (TTM)

Gross Profit

-$15.25M

Operating Income

-$263.90M

EBITDA

-$240.76M

Operating Cash Flow

-$196.48M

Capital Expenditure

-$579.00K

Free Cash Flow

-$197.06M

Cash & ST Invst.

$531.58M

Total Debt

$252.22M

Eikon Therapeutics Performance Analysis

Eikon Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Eikon Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Eikon Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -4.80N/A
20242024-12-31USD -4.830.8%
20252025-12-31USD -6.1627.5%
Eikon Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-4.1%
Q22026-06-30-6.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.03M

N/A

Gross Margin

0.00%

N/A

Market Cap

$631.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.64M

N/A

Employees

384

N/A

Net Income

-$88.41M

N/A

EBITDA

-$88.37M

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$531.58M

N/A

Total Debt

$252.22M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$242.77M

N/A

Short Term Debt

$9.45M

N/A

Return on Assets

-32.20%

N/A

Return on Invested Capital

-36.44%

N/A

Free Cash Flow

-$65.21M

N/A

Operating Cash Flow

-$64.96M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,701.85-0.01%
^DJIDJI
$53,396.81-0.00%
^IXICNASDAQ
$26,314.93-0.01%
BTCBitcoin
$64,721.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$120.07+0.91%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$19.60+0.10%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.95+0.02%
TNONTenon Medical
$12.46+1.29%

Questions About EIKN

What is the current price of Eikon Therapeutics?

Eikon Therapeutics is trading at $13.70 per share.

What is the 52-week range for Eikon Therapeutics?

Over the past 52 weeks, Eikon Therapeutics has traded between $7.90 and $18.00.

How much debt does Eikon Therapeutics have?

As of the most recent reporting period, Eikon Therapeutics reported total debt of $252.22M.

How much cash does Eikon Therapeutics have on hand?

Eikon Therapeutics reported $143.01M in cash and cash equivalents in its most recent financial results.

What is Eikon Therapeutics’s dividend yield?

Eikon Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services